Opus Genetics gains after raising $25 million for vision therapy programs

Opus Genetics

13/02/2026 13:19

** Shares of biotech firm Opus Genetics IRD.O rise 3% to $3.48 premarket

** Co says it raised $25 million in a private share sale led by Adage Capital to fund its vision‑restoring gene therapy programs

** Says it sold over 7.3 million preferred shares at $3.39 each; stock to convert to common after shareholder approval

** Says will use proceeds to advance gene therapy research for inherited eye diseases and for general expenses

** Expects cash runway into H1 2028; sale to close on February 18

** Pipeline includes seven gene therapy programs for rare retinal disorders and one approved eye‑drop product - IRD

** Shares rose ~69% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))